Meanwhile: Advaxis downgraded to Neutral from Buy at H.C. Wainwright H.C. Wainwright analyst Swayampakula Ramakanth downgraded Advaxis (ADXS) to Neutral without a price target. Amgen's (AMGN) termination of a development and collaboration agreement puts ADXS-NEO in limbo, Ramakanth tells investors in a research note. The analyst believes Amgen's withdrawal has "considerably increased" the development risk on ADXS-NEO and potentially ADXS-HOT as well. He steps to the sidelines "until the viability of the programs can be assured."
These guys are always 'a day late and a dollar short',and still out of touch - the very definition of ADXS.
Is it likely that the analyst covering ADXS at HC spoke to Ken or someone else and did not get a good feeling about their strategy going forward? Or are these 'analysts' as clueless as we are?
News 
Market Data 
Discover 
AI
